Esteve launches first inhaled rescue treatment for Parkinson's OFF periods
Spanish privately owned drugmaker Esteve says it has now obtained pricing and financing for an inhaled treatment for OFF periods in Parkinson's disease, which it launched on the Spanish market in mid-February 2023.
Inbrija (levodopa inhalation powder) is the first and indeed only orally inhaled therapy to be indicated for the intermittent treatment of the OFF episodes. Introduced in Spain by Esteve, this advance further strengthens the company's commitment to therapeutic innovation in the neurosciences.
Esteve licensed rights to Inbrija 0in 2021 from the USA’s Acorda Therapeutics (Nasdaq: ACOR), which will receive a significant double-digit percent of the selling price of the drug in Spain in exchange for supply of the product. Esteve last year launched the product in Germany.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze